Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPearson Regulatory News (PSON)

Share Price Information for Pearson (PSON)

Share Price is delayed by 15 minutes
Get Live Data
1,147.50    7.50 (0.66%)
Bid:
1,146.50
Ask:
1,147.50
Spread: 1.00 (0.087%)
Market Cap: £6.89b
PSON Live PriceLast checked at - London Stock Exchange

Intraday Pearson Share Chart

Disposal

7 Jun 2022 07:00

RNS Number : 9604N
Pearson PLC
07 June 2022
 

Pearson Announces Sale of Local K12 Courseware Businesses in Italy & Germany

 

LONDON, 07 JUNE 2022: In March 2021, Pearson, the world's leading learning company, announced a strategic review of its International Courseware local publishing businesses. As part of this review, Pearson already completed the disposal of its Brazilian sistemas business in October 2021 for R$789m (£108m).

 

Today, Pearson announces that it has agreed to sell its local K12 Courseware businesses in Italy and Germany to Sanoma Corporation, a leading European K12 learning services company operating in 11 countries and listed in Nasdaq Helsinki (SAA1V). The headline consideration of this transaction is £163m, which will be paid in cash on completion, subject to typical working capital adjustments. Under the terms of the transaction, Pearson will also enter into an agreement with Sanoma for it to distribute Pearson's English Language Teaching products in Italy.

 

As previously stated, the proceeds of this transaction were anticipated in the decision to commence Pearson's £350m share buyback programme, which is progressing well, with over £100m in shares repurchased since launch.

 

The Italian and German local K12 Courseware businesses had gross assets of c.£135m and net assets of c.£105m as at 31 December 2021[1].The businesses generated c.£90m of revenue and c.£9m of adjusted operating profit in 2021. The enterprise value represents an EV / 2021 EBITDA multiple of 15.5x.

 

In 2021, the businesses that are the subject of strategic review ("strategic review businesses") contributed revenue of £252m, and £22m in adjusted operating profit. The impact of disposals of strategic review businesses on Pearson's 2022 adjusted operating profit will depend upon the timing of transaction completions, but is expected to be c.£15-20m, reflecting the second half weighting of their financial contributions. Operating cash flow for these businesses is weighted to Q4 and the timing of completion is therefore also likely to impact operating cash conversion in 2022. This cash impact will be offset by the transaction working capital adjustment, recorded within cash from investing activities.

 

Pearson continues to make good progress in the remaining areas of the strategic review and will provide a further update on this in due course.

 

BNP Paribas has acted as exclusive financial adviser to Pearson plc regarding the review of its International Courseware local publishing businesses.

 

This announcement contains inside information.

 

---ENDS---

Contacts

Investor Relations 

Jo Russell 

James Caddy 

 +44 (0) 7785 451 266 

 +44 (0) 7825 948 218 

Media 

Tom Steiner 

Gemma Terry 

 +44 (0) 7787 415 891 

 +44 (0) 7841 363 216 

Teneo 

Charles Armitstead

 +44 (0) 7703 330 269 

 


[1] Gross asset value and net asset value figures are unaudited as at 31 December 2021

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DISEASKXELEAEEA
Date   Source Headline
28th Jul 20239:31 amRNSCommittee Changes
27th Jul 20239:48 amRNSDirector Declaration
19th Jul 20234:13 pmRNSDirector/PDMR Shareholding
4th Jul 20239:10 amRNSDirector/PDMR Shareholding
3rd Jul 20233:38 pmRNSTotal Voting Rights
14th Jun 20235:17 pmRNSHolding(s) in Company
1st Jun 202312:32 pmRNSBlock listing Interim Review
1st Jun 202312:28 pmRNSTotal Voting Rights
26th May 20234:48 pmRNSHolding(s) in Company
19th May 20233:00 pmRNSDirector/PDMR Shareholding
17th May 20234:50 pmRNSDirector/PDMR Shareholding
16th May 20234:16 pmRNSDirector/PDMR Shareholding
10th May 20234:30 pmRNSDirector/PDMR Shareholding
10th May 202310:49 amRNSDirectorate Change
9th May 20234:15 pmRNSHolding(s) in Company
9th May 20239:00 amRNSPearson: Generative AI Strategy Update
4th May 20234:30 pmRNSDirector/PDMR Shareholding
4th May 20234:30 pmRNSDirector/PDMR Shareholding
4th May 20234:30 pmRNSDirector/PDMR Shareholding
3rd May 20234:13 pmRNSHolding(s) in Company
2nd May 20233:57 pmRNSTotal Voting Rights
28th Apr 20231:11 pmRNSResult of AGM
28th Apr 20237:00 amRNSPearson 2023 Q1 Trading Update
20th Apr 20234:19 pmRNSHolding(s) in Company
11th Apr 20239:17 amRNSHolding(s) in Company
4th Apr 20234:30 pmRNSDirector/PDMR Shareholding
4th Apr 20234:00 pmRNSHolding(s) in Company
4th Apr 20237:00 amRNSDirector/PDMR Shareholding
3rd Apr 20233:00 pmRNSTotal Voting Rights
31st Mar 20233:44 pmRNSForm 20-F for the year ended 31 December 2022
31st Mar 20232:29 pmRNSHolding(s) in Company
28th Mar 202311:17 amRNSDirector Declaration
27th Mar 20234:05 pmRNSHolding(s) in Company
24th Mar 202312:30 pmRNSNotice of AGM
23rd Mar 20237:00 amRNSPearson Completes Acquisition of PDRI
21st Mar 20237:00 amRNSPearson to sell POLS
16th Mar 20233:09 pmRNSAnnual Financial Report
16th Mar 202311:28 amRNSDirector Declaration
7th Mar 20234:36 pmRNSDirector/PDMR Shareholding
3rd Mar 20237:00 amRNSPearson 2022 Preliminary Results
2nd Mar 20233:37 pmRNSCommittee Change
1st Mar 202310:10 amRNSTotal Voting Rights
8th Feb 20232:37 pmRNSHolding(s) in Company
3rd Feb 20234:23 pmRNSDirector/PDMR Shareholding
1st Feb 202311:10 amRNSTotal Voting Rights
18th Jan 20237:00 amRNSPearson 2022 Trading Update
4th Jan 20233:04 pmRNSDirector/PDMR Shareholding
3rd Jan 20239:25 amRNSTotal Voting Rights
19th Dec 202212:02 pmRNSDirector/PDMR Shareholding
19th Dec 202212:00 pmRNSPearson to Acquire PDRI

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.